Pulmonary Hypertension: A Patient-Centered, Team-based Approach to Optimizing Outcomes in PAH and CTEPH

Release Date :
November 15, 2018
Expiration Date :
November 15, 2019
FACULTY

Ioana R. Preston, MD, FACCP
Associate Professor of Medicine
Tufts University School of Medicine
Director, Pulmonary Hypertension Center
Tufts Medical Center
Boston, Massachusetts

PROGRAM OVERVIEW

PH is a disorder of the pulmonary vasculature and complication of many chronic diseases that is estimated to affect 10% to 20% of the general population. Both conditions involve chronically elevated pressure in the pulmonary arteries that can eventually lead to right-sided heart failure. Morbidity and mortality are poor among patients with PAH or CTEPH, particularly with no therapeutic intervention. The overlaps in clinical features and important differences (and similarities) in treatment between these disorders requires that healthcare providers must have a keen understanding of early diagnostic and evidence-based treatment approaches for each disorder to optimize outcomes in these patients.

TARGET AUDIENCE

This educational initiative has been designed for hospital-based healthcare providers, including physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists involved in the management of patients with PAH and CTEPH.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Identify strategies to screen and improve early recognition of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
  • Apply guideline recommendations to the accurate diagnosis of PAH and CTEPH
  • Develop a guideline-directed, evidence-based management plan for PAH and CTEPH that includes consideration of novel therapies and current clinical trial data
  • Establish a multidisciplinary, patient-centered approach to care for patients with PAH or CTEPH
DIRECTIONS TO THE LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of November 15, 2018, through November 15, 2019, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integrity Continuing Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Integrity Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for a total of 0.8 contact hour(s) (0.08 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number – JA4008162-9999-18-416-H01-P)
Type of Activity: Application

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.8 contact hours. Designated for 0.1 hours of pharmacotherapy for Advance Practice Registered Nurses.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or hms@integrityce.com.
For information about ACPE or ANCC accreditation of this activity, please contact Postgraduate Institute for Medicine at (303) 799-1930 or inquires@pimed.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education and Postgraduate Institute for Medicine require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education and Postgraduate Institute for Medicine for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Integrity Continuing Education and Postgraduate Institute for Medicine are committed to providing learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest or a commercial interest.

The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Ioana Preston, MD, FACCP
Consultant: Acceleron, Actelion, Gilead, Liquidia, Pfizer, United Therapeutics
Grants to TMC: Acceleron, Actelion, Bayer, Complexa, Gilead, Liquidia, United Therapeutics

The following planner and manager, Michelle R. Rizzo, ELS, hereby states that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. The PIM planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine and Integrity Continuing Education do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10

Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

This CME activity is provided by Integrity Continuing Education.

This CEU/CNE activity is co-provided by Postgraduate Institute for Medicine and Integrity Continuing Education.

SUPPORTER ACKNOWLEDGMENT

Supported by an educational grant from Actelion Pharmaceuticals US, Inc.

Continue to Pretest